We previously reported that the Class IC antiarrythmic drug flecainide (FLEC) inhibits RyR2 channels in the open state, suppresses Ca2+ waves and prevents CPVT in mice and humans [21, 22]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.